{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:41:31Z","timestamp":1773283291470,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jgar.2016.11.011","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T02:47:20Z","timestamp":1486176440000},"page":"164-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Fosfomycin: In vitro efficacy against multidrug-resistant isolates beyond urinary isolates"],"prefix":"10.1016","volume":"8","author":[{"given":"Tulin","family":"Demir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuncay","family":"Buyukguclu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2016.11.011_bib0005","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkq237","article-title":"Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.11.011_bib0010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1157\/13095372","article-title":"Activity of fosfomycin against extended-spectrum \u03b2-lactamase producing Escherichia coli and Klebsiella pneumoniae","volume":"24","author":"de Cueto","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.jgar.2016.11.011_bib0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2009.10.019","article-title":"Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2016.11.011_bib0020","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1128\/AAC.00402-12","article-title":"Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms","volume":"56","author":"Neuner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2016.11.011_bib0025","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0030","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ijid.2013.04.005","article-title":"Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial isolates recovered from community- and hospital-acquired urinary tract infections in Turkey","volume":"17","author":"Demir","year":"2013","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0035","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0040","series-title":"Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. Document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2016.11.011_bib0045","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition. Document M07-A10","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2016.11.011_bib0050","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2016"},{"key":"10.1016\/j.jgar.2016.11.011_bib0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/jinf.2002.1091","article-title":"A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection","volume":"46","author":"Farrell","year":"2003","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2016.11.011_bib0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jmii.2010.08.012","article-title":"Antimicrobial susceptibilities of urinary extended-spectrum \u03b2-lactamase producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan","volume":"44","author":"Liu","year":"2011","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2016.11.011_bib0065","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/jac\/dkh218","article-title":"In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics","volume":"53","author":"Alhambra","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.11.011_bib0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0075","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-011-0132-6","article-title":"Extended-spectrum \u03b2-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy","volume":"39","author":"Meier","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2016.11.011_bib0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1469-0691.2007.01852.x","article-title":"Other antimicrobials of interest in the era of extended-spectrum \u03b2-lactamases: fosfomycin, nitrofurantoin and tigecycline","volume":"14","author":"Garau","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2016.11.011_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/dkg028","article-title":"An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project","volume":"51","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.11.011_bib0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1179\/joc.1997.9.6.394","article-title":"In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study","volume":"9","author":"Garcia-Rodriguez","year":"1997","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2016.11.011_bib0095","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2217\/fmb.10.47","article-title":"Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials","volume":"5","author":"Samonis","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2016.11.011_bib0100","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1128\/AAC.01834-09","article-title":"Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes","volume":"54","author":"Wachino","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2016.11.011_bib0105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/phar.1434","article-title":"Fosfomycin for the treatment of resistant Gram-negative bacterial infections: insights from the Society of Infectious Diseases Pharmacists","volume":"34","author":"Reffert","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2016.11.011_bib0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-009-0833-2","article-title":"Fosfomycin: an old, new friend?","volume":"29","author":"Popovic","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","article-title":"Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0120","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/cid\/ciu580","article-title":"FOSIMI Investigators: Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial","volume":"59","author":"del R\u00edo","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0125","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000348572","article-title":"In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates","volume":"91","author":"Lingscheid","year":"2013","journal-title":"Pharmacology"},{"key":"10.1016\/j.jgar.2016.11.011_bib0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2016.11.011_bib0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1155\/2013\/645018","article-title":"Determination of susceptibility to fosfomycin and tigecycline of Enterobacteriaceae, particularly Escherichia coli isolates, producing extended-spectrum \u03b2-lactamases from multiple regional Canadian hospitals","volume":"24","author":"Beuk","year":"2013","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jgar.2016.11.011_bib0145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","article-title":"What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline","volume":"37","author":"Livermore","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2016.11.011_bib0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.diagmicrobio.2006.11.015","article-title":"In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum \u03b2-lactamase-producing Escherichia coli isolated from urine and blood","volume":"58","author":"Ko","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2016.11.011_bib0155","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1128\/JCM.02353-09","article-title":"Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"48","author":"Rodriguez-Bano","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2016.11.011_bib0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517300127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517300127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T03:48:35Z","timestamp":1568778515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517300127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":32,"alternative-id":["S2213716517300127"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2016.11.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fosfomycin: In vitro efficacy against multidrug-resistant isolates beyond urinary isolates","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2016.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}